Drug Trial Radar · NCT05546268
Study of Oral MRT-2359 in Selected Cancer Patients
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
174
Planned (sponsor's estimate)
Start
Oct 12, 2022
Primary completion
Dec 2026
Study completion Nov 2027
Sponsor
- Lead sponsor
- Monte Rosa Therapeutics, IncIndustry
- Sponsor type
- Industry
- First posted
- Sep 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 1/2, open-label, multicenter study is conducted in patients with previously treated selected solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), high-grade neuroendocrine cancer of any primary site, diffuse large B-cell lymphoma (DLBCL), and tumors with L-MYC or N-MYC amplification. Patients receive escalating doses of a GSPT1 molecular glue degrader MRT-2359 to determine safety, tolerability, maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of MRT-2359. Once the MTD and/or RP2D is identified, additional patients enroll to Phase 2 study, which includes molecular biomarkers stratification or selection, namely expression or amplification of L-MYC and N-MYC genes, hormone receptor positive (HR)-positive, human epidermal growth factor 2 (HER2)-negative breast cancer and prostate cancer.
Conditions
- NSCLC
- SCLC
- High Grade Neuroendocrine Cancer
- DLBCL
- L-MYC and N-MYC Amplified Solid Tumors
- NSCLC With High or Low L-MYC or N-MYC Expression
- HR-positive, HER2-negative Breast Cancer
- Prostate Cancer
Interventions
Oral MRT-2359Drug
Orally administered tablets of MRT-2359.
Oral MRT-2359Drug
Orally administered tablets of MRT-2359.
Oral MRT-2359Drug
Orally administered tablets of MRT-2359.
Oral MRT-2359Drug
Orally administered tablets of MRT-2359.
Oral MRT-2359Drug
Orally administered tablets of MRT-2359 in conjunction with intramuscular administration of fulvestrant.
Oral MRT-2359Drug
Orally administered tablets of MRT-2359 in conjunction with orally administered enzalutamide.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1 Evaluates safety and tolerability of MRT-2359 over a 28-day cycle by the occurrence and frequency of dose limiting toxicities (DLTs) for determination of the MTD and/or RP2DTime frame: 28 days
- Phase 2 Evaluates preliminary anti-tumor activity of MRT-2359 by overall response rate (ORR) as determined by RECIST 1.1Time frame: 56 days (up to approximately 24 months from screening to end of study participation
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Honor Health Research Institute
Scottsdale, Arizona
University of California San Diego
San Diego, California
Yale University
New Haven, Connecticut
University of Kansas Cancer Center
Lawrence, Kansas
Dana Farber Cancer Institute
Boston, Massachusetts
Henry Ford Cancer Institute
Detroit, Michigan
South Texas Accelerated Research Therapeutics (START) Midwest
Grand Rapids, Michigan
Washington University
St Louis, Missouri
Memorial Sloan Kettering Cancer Center
New York, New York
Columbia University Irving Medical Centre
New York, New York
Sarah Cannon Research Institute
Nashville, Tennessee
Mary Crowley Cancer Research
Dallas, Texas
MD Anderson Cancer Center
Houston, Texas
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas
South Texas Accelerated Research Therapeutics (START) Mountain Region
West Valley City, Utah
Virginia Cancer Specialists Research Institute
Fairfax, Virginia
Fred Hutchinson Cancer Center
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.